Official Title
National Retrospective Monitoring of Patients With Acute Leukemia Infected by COronaVirus Disease 2019 (COVID-19)
Brief Summary

The COVID-19 epidemic (Coronavirus Disease 2019) currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). Epidemiologically, acute myeloblastic leukemias (AML) are the most common of acute leukemias. The incidence of acute lymphoblastic leukemia (ALL) is 900 new cases in France in 2018, of which 57% in humans. The treatments administered to AML and ALL patients induce variable immunosuppression: neutropenia, neuropathy, deficits in humoral or cellular immunity or combinations of these deficits. Patients with AML or ALL therefore represent a population at high risk of developing a serious form in the event of infection with SARS-CoV-2. To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in the population of patients with acute leukemia. The main objective of the study is to determine the clinical and biological prognostic factors during SARS-CoV-2 infection in patients with acute leukemia.

Completed
Acute Myeloblastic Leukemia
Acute Lymphoblastic Leukemia
SARS-CoV-2
Eligibility Criteria

Inclusion Criteria:

- Diagnosis of acute leukemia according to WHO criteria 2016 ≤ 5 years

- Diagnosis of a proven or probable SARS-CoV-2 infection according to the following
criteria:

1. Proven infection: positive Polymerase Chain Reaction (PCR) regardless of the
radio-clinical picture (other tests made available later and having good
diagnostic performance will be accepted)

2. Probable infection: negative PCR but association of

1. Evocative clinical signs, of recent installation: fever, respiratory signs
(cough, dyspnea, chest pain), body aches, sore throat, rhinorrhea, headache,
diarrhea / abdominal pain, frank asthenia, loss of taste / smell,
conjunctivitis, type of frostbite AND

2. evocative radiological signs, on CT: diffuse or diffuse aspect of frosted
glass, condensations including pseudo-nodular condensations, association of
frosted glass and condensation within the same lesion, nodules and
micronodules, thickening of the interlobular septa) or on chest radiography:
interstitial, alveolo-interstitial or alveolar syndrome, single or bilateral
AND

3. absence of differential diagnosis

Exclusion Criteria:

- None

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Chu Amiens
Amiens, France

CHU ANGERS - Maladies du sang
Angers, France

Ch Avignon
Avignon, France

CH de la Côte Basque - Hématologie
Bayonne, France

CHU Caen - IHBN - Hématologie Clinique
Caen, France

Centre Hospitalier Sud Francilien
Corbeil-essonnes, France

Centre Hospitalier de Dunkerque
Dunkerque, France

CHU de Grenoble - Hopital Michallon
Grenoble, France

Centre Hospitalier du Mans
Le Mans, France

Hôpital Saint Vicent de Paul
Lille, France

Chu Limoges
Limoges, France

Institut Paoli-Calmettes - Hématologie 2
Marseille, France

HOPITAL SAINT ELOI - Hematologie
Montpellier, France

HOPITAL E. MULLER - Hématologie
Mulhouse, France

CHU HOTEL DIEU - Hématologie Clinique
Nantes, France

CHU Caremeau
Nîmes, France

CENTRE HOSPITALIER SAINTJEAN - Hématologie Clinique
Perpignan, France

Bordeaux Pessac
Pessac, France

Centre Hospitalier Lyon Sud
Pierre-Bénite, France

CHU Reims - Hôpital Robert Debré - Hématologie Clinique
Reims, France

CHU Pontchaillou - Hématologie
Rennes, France

Chu de La Reunion - Site Sud
Saint-pierre, France

Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, France

Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie
Toulouse, France

CHU de Brabois
Vandœuvre-lès-Nancy, France

Centre Hospitalier de Versailles
Versailles, France

Institut Gustave Roussy
Villejuif, France

Pierre-Yves DUMAS, Dr, Principal Investigator
French Innovative Leukemia Organisation

French Innovative Leukemia Organisation
NCT Number
MeSH Terms
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Myeloid, Acute